Pifeltro™ (doravirine), Delstrigo™ (doravirine/lamivudine/tenofovir disoproxil fumarate) – Expanded indications
January 27, 2022, the FDA approved Merck’s Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate).
Download PDF
